Following a full submission
AWMSG advice |
||
| Status: Not recommended | ||
Teriparatide (Forsteo®) is not recommended for use within NHS Wales for the treatment of osteoporosis in men at increased risk of fracture. The AWMSG Scrutiny Panel have considered teriparatide suitable for a limited reassessment - see teriparatide AWTTC ref 6561 for more details. |
||
|
||
Medicine details |
||
| Medicine name | teriparatide (Forsteo®) | |
| Formulation | 20 micrograms/80 microlitres solution for injection | |
| Reference number | 306 | |
| Indication | Treatment of osteoporosis in men at increased risk of fracture |
|
| Company | Eli Lilly & Co Ltd | |
| BNF chapter | Endocrine system | |
| Submission type | Full | |
| Status | Not recommended | |
| Advice number | 2108 | |
| Scrutiny Panel meeting date | 06/02/2025 | |
| NMG meeting date | 17/09/2008 | |
| AWMSG meeting date | 15/10/2008 | |
| Ratification by Welsh Government | 18/11/2008 | |
| Date of issue | 25/11/2008 | |
| Further information The AWMSG Scrutiny Panel have considered teriparatide suitable for a limited reassessment - see teriparatide AWTTC ref 6561 for more details. |
||